Short Squeeze? Small Biotech- ACRX

After getting hammered in July from the FDA delaying approval on its' latest drug for pain relief, Bears have been piling on making an incredible 20% of the float short. Recent buy ratings from analysts could be the catalyst to get a short squeeze going to begin filling the gap left from the huge 40%+ drop in July. If momentum can carry the stock past 8, then 9 is a real possibility in a short amount of time. Two analysts have a hold rating while seven analysts have a buy rating including Jefferies Group that has a price target of $16.
EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
ZH 繁體中文
AR العربية
HE עברית
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Private Messages Chat Sign Out